ONCOGALFARMA: Development of new complementary therapies for the treatment of oncological diseases

Development of new complementary therapies for the treatment of oncological diseases

GalChimia, Oncostellae, and AMSLab participates in the research project Oncogalfarma, whose goal is to develop new complementary therapies for the treatment of oncological diseases. The research is centered in the fields of inhibitors of protein–protein interactions (PPI) and nuclear receptors. The project has been financed by the Government of Galicia and co-financed by the European Regional Development Fund through the subprogramme CONECTA PEME. The total funding granted is €189,943.59.

Comunication and Dissemination

• Poster DEVELOPMENT OF NOVEL DRUG CANDIDATES FOR SELECTIVE INHIBITION OF Bcl-2 PROTEIN–PROTEIN INTERACTIONS presented at the SEQT National Congress (Santiago de Compostela, 2022).

GalChimia thanks all the partners in the Oncogalfarma project for their involvement and teamwork, which have been key to the success of the project.